LLF-KY (6666) reported revenue of NT$78.3 million for Oct 2026, +16.6% year on year and +1.3% from the previous month. Revenue for Jan–Oct 2026 was NT$998.2 million (+8.4% year on year).
In Oct 2026, it ranked No. 87 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$78.3 million | +16.6% | +1.3% |
| Sep 2026 | NT$77.3 million | -25.5% | -4.1% |
| Aug 2026 | NT$80.6 million | +15.9% | -14.9% |
| Jul 2026 | NT$94.6 million | +12.5% | -43.6% |
| Jun 2026 | NT$167.8 million | +29.5% | +6.4% |
| May 2026 | NT$157.6 million | +35.1% | +37.7% |
| Apr 2026 | NT$114.5 million | +12.2% | +12.5% |
| Mar 2026 | NT$101.8 million | -14.8% | +74.2% |
| Feb 2026 | NT$58.4 million | -12.5% | -13.4% |
| Jan 2026 | NT$67.4 million | +8.9% | -42.9% |
| Dec 2025 | NT$118.2 million | +13.6% | +59.7% |
| Nov 2025 | NT$74 million | +14.7% | +10.3% |
| Oct 2025 | NT$67.1 million | -4.1% | -35.3% |
| Sep 2025 | NT$103.7 million | -4.7% | +49.1% |
| Aug 2025 | NT$69.5 million | -31.2% | -17.3% |
| Jul 2025 | NT$84.1 million | -4.9% | -35.1% |
| Jun 2025 | NT$129.5 million | -1.0% | +11.1% |
| May 2025 | NT$116.6 million | +4.5% | +14.4% |
| Apr 2025 | NT$102 million | -5.9% | -14.6% |
| Mar 2025 | NT$119.5 million | +10.2% | +79.0% |
| Feb 2025 | NT$66.7 million | -9.4% | +7.8% |
| Jan 2025 | NT$61.9 million | +9.6% | -40.5% |
| Dec 2024 | NT$104.1 million | -0.2% | +61.2% |
| Nov 2024 | NT$64.5 million | -23.4% | -7.8% |
| Oct 2024 | NT$70 million | +28.6% | -35.7% |
Jan–Oct 2026 cumulative: NT$998.2 million (+8.4% YoY)
Other Biotech & Medical companies
Compare with peers: LLF-KY vs PEC / LLF-KY vs Lotus Pharm / LLF-KY vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16